[1] Ofrin RH, Buddha N, Htike MM, et al.Strengthening risk commun-ication systems for public health emergencies in the WHO South-East Asia Region[J]. WHO South East Asia J Public Health,2020,9(1):15-20. [2] Geneva: World Health Organization. International Health Regu-lations (2005), 2nd edition[EB/OL]. (2005-05-23)[2020-08-05]. https://apps.who.int/iris/bitstream/handle/10665/43883/9789241580410_eng.pdf;jsessionid=2235E048F3EA0FDC617685709535EEB0?sequence=. [3] Geneva: World Health Organization. Communicating risk in public health emergencies: a WHO guideline for emergency risk communication (ERC) policy and practice[EB/OL]. (2018-07-03)[2020-08-05]. https://apps.who.int/iris/bitstream/handle/10665/259807/9789241550208-eng.pdf;jsessionid=378F4B716BCF7DF949752B278187E098?sequence=2. [4] Gong SW, Zhang L, Huang JM, et al.Drug safety and drug risk management[J]. China Pharmacy(中国药房), 2007(22): 1687-1690. [5] Li HQ, Gong L, Fan CM.The formation mechanism of the public’s coping behavior in drug safety events[J]. Journal of Public Manag-ement(公共管理学报), 2019, 16(3): 97-107. [6] Davies NM, Thomas KH.The Food and Drug Administration and varenicline: should risk communication be improved?[J]. Addiction,2017,112(4): 555-558. [7] Edwards B, Chakraborty S.Risk communication and the pharma-ceutical industry: what is the reality?[J]. Drug Saf, 2012, 35(11): 1027-1040. [8] Sun WC.Study on the cognition of stakeholders on drug safety risk communication [D]. Beijing University of Chinese Medicine, 2013. [9] Zhang J, Zhang TF.Research on risk communication in the United States: academic evolution, core proposition and key factors[J].Chinese Journal of Journalism & Communication(国际新闻界), 2009(9): 95-101. [10] Teasdale A, Elder D, Nims RW .ICH Q9 quality risk management[M]. ICH Quality Guidelines, 2017. [11] Xu R, Liu Y, Wei XH, et al.Study on the ways of drug risk infor-mation communication based on empirical analysis[J]. Pharma-ceutical Education(药学教育), 2018, 34(1): 62-66. [12] Lu KR, Hu M, Jiang XH.Consideration on risk communication method in the drug risk management[J]. China Pharmacy(中国药房), 2010(17): 1545-1549. [13] Wei J, Pan WS, Yang Y.Communication to the public guidance of FDA's drug safety information and the inspiration to our country[J].Chinese Journal of New Drugs(中国新药杂志), 2009, 18(14): 1287-1290. [14] Food and Drug Administration. Guidance Drug Safety Information-FDA's Communication to the Public. [EB/OL].(2007-03-01) [2020-08-05]. https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications. [15] Wu SF, Jin Y, Chang H, et al.Drug risk communication in the European Union and United States between regulators and the public[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(2): 87-92. [16] Rollman JE, Heyward J, Olson L, et al. Assessment of the FDA risk evaluation and mitigation strategy for transmucosal immediate-release fentanyl products[J]. JAMA,2019, 19: 321(7): 676-685. [17] Guideline on good pharmacovigilance practices (GVP)- ModuleXV-Safety communication (Rev 1) [EB/OL]. (2013-01-24)[2020-08-05]. https://www.ema.europa.eu/en/documents/scientificguideline. [18] European Medicines Agency. Guidelines on good pharmacovigilance practices[EB/OL]. (2020-06-23)[2020-08-05]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345. jsp. [19] Xie YM, Tian F.Interpretation of guidelines on good pharmaco-vigilance practices for European Union[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2013, 38(18): 2963-2968. [20] Xu L, Zhao YJ, Li F, et al.Brief introduction and its implication on the drug risk management system in Japan[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2010, 26(10): 784-789. [21] McEwen J. Risk management from an Asian/Pacific Rim regulatory perspective[J]. Drug Saf, 2004, 27(8): 491-497. [22] Shin JY, Jung SY, Ahn SH, et al.New initiatives for pharma-covigilance in South Korea: introducing the Korea Institute of Drug safety and risk management (KIDS)[J]. Pharmacoepidemiol Drug Saf, 2014, 23(11): 1115-1122. [23] The Directorate General of Drug Administration,The People’s Republic of Bangladesh. Communication policy. [EB/OL].(2017-09-25) [2020-08-05]. http://www.dgda.gov.bd/index.php/laws-and-policies. [24] Right to Information Act. Ministry of Hearth and Indigenous Medical Services, Sri Lanka[EB/OL]. (2018-07-01) [2020-08-05]. http://www.health.gov.lk/moh_final/english/others.php?pid=159. [25] Xinhua News Agency. Law of the PRC Governing the Management of Pharmaceutical Products [EB/OL]. (2019-08-26) [2020-08-05]. http://www.gov.cn/xinwen/2019-08/26/content_5424780.htm. [26] Jia YX.Research on the visualization system construction of drug safety knowledge towards decision support[D]. Jilin University, 2019. |